Early detection, prevention and management of cutaneous adverse events due to sorafenib

Recommendations from the Sorafenib Working Group

Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco Merlano, Alessandro D'Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.

Original languageEnglish
Pages (from-to)378-386
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume82
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Skin
Protein-Tyrosine Kinases
Guidelines
sorafenib
Incidence
Pharmaceutical Preparations
Neoplasms

Keywords

  • Cutaneous adverse events
  • Guidelines
  • Hand-foot skin reaction
  • Prevention
  • Sorafenib
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Early detection, prevention and management of cutaneous adverse events due to sorafenib : Recommendations from the Sorafenib Working Group. / Bracarda, Sergio; Ruggeri, Enzo Maria; Monti, Marcello; Merlano, Marco; D'Angelo, Alessandro; Ferraù, Francesco; Cortesi, Enrico; Santoro, Armando.

In: Critical Reviews in Oncology/Hematology, Vol. 82, No. 3, 06.2012, p. 378-386.

Research output: Contribution to journalArticle

Bracarda, Sergio ; Ruggeri, Enzo Maria ; Monti, Marcello ; Merlano, Marco ; D'Angelo, Alessandro ; Ferraù, Francesco ; Cortesi, Enrico ; Santoro, Armando. / Early detection, prevention and management of cutaneous adverse events due to sorafenib : Recommendations from the Sorafenib Working Group. In: Critical Reviews in Oncology/Hematology. 2012 ; Vol. 82, No. 3. pp. 378-386.
@article{7b53946280cd4544afd42b80e9569ad8,
title = "Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group",
abstract = "Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.",
keywords = "Cutaneous adverse events, Guidelines, Hand-foot skin reaction, Prevention, Sorafenib, Targeted therapy",
author = "Sergio Bracarda and Ruggeri, {Enzo Maria} and Marcello Monti and Marco Merlano and Alessandro D'Angelo and Francesco Ferra{\`u} and Enrico Cortesi and Armando Santoro",
year = "2012",
month = "6",
doi = "10.1016/j.critrevonc.2011.08.005",
language = "English",
volume = "82",
pages = "378--386",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Early detection, prevention and management of cutaneous adverse events due to sorafenib

T2 - Recommendations from the Sorafenib Working Group

AU - Bracarda, Sergio

AU - Ruggeri, Enzo Maria

AU - Monti, Marcello

AU - Merlano, Marco

AU - D'Angelo, Alessandro

AU - Ferraù, Francesco

AU - Cortesi, Enrico

AU - Santoro, Armando

PY - 2012/6

Y1 - 2012/6

N2 - Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.

AB - Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.

KW - Cutaneous adverse events

KW - Guidelines

KW - Hand-foot skin reaction

KW - Prevention

KW - Sorafenib

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84861191918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861191918&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.08.005

DO - 10.1016/j.critrevonc.2011.08.005

M3 - Article

VL - 82

SP - 378

EP - 386

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -